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Abstract Cardiovascular (CV) morbidity and mor-
tality increase with the severity of kidney disease,
reaching 30 times higher mortality rates in dialysis
patients compared with the general population.
Although dyslipidemia is a well-established CV risk
factor in the general population, the relationship
between lipid disorders and CV risk in patients with
chronic kidney disease (CKD) is less clear. Despite the
clear evidence that statins reduce the risk of athero-
sclerotic events and death from cardiac causes in
individuals without CKD, the use of statins in patients
with kidney disease is significantly less frequent. For a
long time, one of the explanations was the lack of a
prospective, randomized, controlled study designed
specifically to CKD patients. After recent publication
of the data from Study of Heart and Renal Protection
trial, given the safety and potential efficacy of statins,
this lipid-lowering treatment should be administered
more frequently to individuals with CKD stage 1–4, as
well as those undergoing dialysis.
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Introduction
Cardiovascular disease (CVD) has been identified as
the main cause of death among patients with end-stage
renal disease (ESRD). It has been reported that the
cardiovascular (CV) mortality is up to 30 times higher
in dialysis patients than in the general population [1].
Moreover, there is evidence that cardiovascular events
occur more frequently already at early stages of
chronic kidney disease (CKD) and the cardiovascular
mortality increases with the severity of kidney disease
[2]. Altogether, patients with CKD stage 3 and 4 are
more likely to die of cardiovascular causes than to
reach ESRD requiring renal replacement therapy [3].
Although dyslipidemia is a well-established car-
diovascular risk factor in the general population, the
relationship between lipid disorders and CV risk in
patients with chronic kidney disease is less clear. The
causes of lipid metabolism disorders in patients
suffering from CKD are complex and depend on the
degree of renal failure. In a cross-sectional study of
over 16,000 patients from NHANES III population,
lower GFR was associated with decreased apolipo-
protein A-I (ApoA-I) and increased apolipoprotein B
(ApoB) serum concentrations [4].
The role of HMG-Co-A reductase inhibitors (stat-
ins) in lowering the cardiovascular risk in the general
population is well established. In a meta-analysis of
randomized trials, statin therapy was calculated to
reduce the risk of major coronary events, coronary
revascularization, and stroke by approximately 20 %
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for each 1 mmol/L reduction in LDL cholesterol [5].
The efficacy and safety of statins at early stages of
CKD have been shown in large prospective and
retrospective studies [6–19].
According to the European Best Practice Guide-
lines (EBPG) [20] and American Kidney Disease
Outcomes Quality Initiative (K/DOQI) guidelines
[21], the presence of kidney disease should be
considered as a major risk factor for atherosclerosis
and CVD progression. Therefore, patients with CKD
are potential candidates for treatment with lifestyle
changes and lipid-lowering drugs, mainly statins.
Lipid abnormalities at different stages of CKD
Non-dialysis patients with CKD
Non-nephrotic CKD patients
The atherogenic lipid profile in patients with CKD is
characterized by lower levels of high-density lipopro-
teins (HDL), higher triglyceride (TG), ApoB, lipopro-
tein(a) [Lp(a)], remnant intermediate (IDL), and very
low-density lipoproteins (VLDL) as well as a greater
proportion of oxidized low-density lipoproteins (ox-
LDL). The degree of disturbances in lipoprotein
metabolism is associated with the rate of declining
of glomerular filtration rate (GFR).
The main dyslipidemic disturbance observed in
CKD patients is the elevated concentration of
triglycerides and TG-rich VLDL and IDL remnants
[22, 23]. Decreased activity of peripheral lipoprotein
lipase (LPL) and hepatic lipase (HL) seems to be
the main cause of these lipids abnormalities. One
potential mechanism responsible for increased TG
levels in CKD appears to be the elevated apolipo-
protein C-III (ApoC-III) concentration, a direct
inhibitor of LPL [24]. Moreover, several lines of
evidence suggest a role for the hyperparathyroidism
in the delayed catabolism of TG [25, 26]. Besides
the impaired lipolysis, a downregulation of lipopro-
tein receptors may be involved in the development
of dyslipoproteinemia in patients with chronic
kidney disease. A linkage between decreased clear-
ance of TG-rich lipoproteins and reduced expression
of hepatic LDL receptor-related protein (LRP) and
VLDL receptor has been found in experimental
models of CKD [27, 28].
In patients with CKD, total and serum LDL
cholesterol concentrations are usually within the target
range or even lower. Additionally, the plasma con-
centrations of lipid subfractions may not fully reflect
the CV risk. Patients with chronic kidney disease may
have a greater proportion of oxidized LDL particles,
which are recognized by scavenger receptors and
induce the formation of foam cells in atherosclerotic
plaques [29, 30]. Furthermore, LDL particles in CKD
patients tend to be smaller and denser, therefore more
atherogenic [31, 32].
Low serum HDL cholesterol concentration is
observed in the majority of patients with kidney
disease. It is most probably caused by a decreased
activity of lecithin cholesterol acetyltransferase
(LCAT), an enzyme involved in esterification of
cholesterol and maturation of HDL from pre-b-HDL
to HDL3 and HDL2 [33, 34]. Increased activities of
cholesterol ester transfer protein (CETP) and acyl
CoA: cholesterol acyltransferase (ACAT) are also
related to the lower HDL concentration in CKD [35].
Moreover, patients with kidney disease have been
shown to have lower plasma concentration of ApoA-I
and ApoA-II due to reduced expression of these
proteins in the liver [36]. The change in serum HDL
concentration may also be affected by the presence of
inflammation and decreased albumin concentration in
patients with renal failure [22].
Nephrotic syndrome patients
Elevated serum concentrations of total and LDL
cholesterol as well as increased serum triglycerides
concentrations are typical lipid abnormalities in
patients with nephrotic syndrome [37]. Both protein-
uria and hypoalbuminemia stimulate the activity of
3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reduc-
tase and ACAT [38], as well as may decrease the
expression of the LDL receptor in the liver [39].
Impaired clearance of TG-rich lipoproteins [40] and
elevated hepatic synthesis of VLDL [41] seem to be
the main causes of hypertriglyceridemia in patients
with massive proteinuria.
The results of HDL measurements in patients with
nephrotic syndrome are inconsistent. Some authors
have reported higher [42] levels of HDL cholesterol,
while others have found lower [43] or normal [44]
concentration of this lipoprotein in the presence of
proteinuria.
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Dialysis-dependent CKD patients
Dyslipidemia in hemodialysis patients is characterized
by hypertriglyceridemia, low serum HDL concentra-
tion, and usually normal levels of total and LDL
cholesterol [45–47] similar to the non-dialysis popu-
lation with CKD. It has been observed, however, that
additional factors like repeated use of heparin [48] or
type of membranes used [49] may affect lipid metab-
olism in these patients.
In the majority of published studies, peritoneal
dialysis patients had more atherogenic lipid profile
(higher total and LDL cholesterol, triglycerides and
Lp(a) concentration, greater proportion of oxidized
and small, dense LDL particles) than those on
hemodialysis [31, 32, 50–52]. Two important factors
may explain this phenomenon. First, glucose absorp-
tion from the dialysate solution and coexisting
insulin resistance may promote TG synthesis through
elevated availability of free fatty acids [53, 54].
Secondly, the loss of protein, including apolipopro-
teins, across the peritoneal membrane may lead to
lipid abnormalities similar to those in the nephrotic
syndrome [55].
Lipid abnormalities in patients with CKD
and cardiovascular disease
Non-dialysis patients with CKD
Non-nephrotic CKD patients
Patients with chronic kidney disease have higher
prevalence of both traditional and non-traditional CV
risk factors than those with normal kidney function
[56–58]. In a prospective cohort study of 17,898
participants, including 807 patients with CKD (esti-
mated GFR between 15 and 59 mL/min/1.73 m2)
followed for 10.5 years, Muntner et al. [4] evaluated
the relationship between total cholesterol and TG
levels and major coronary events. They found that
participants with increased total cholesterol or triglyc-
eride serum concentration suffered more coronary
events irrespective of baseline eGFR. Moreover,
lipoprotein(a) concentration and Lp(a) phenotype,
especially small Lp(a), were described as important
cardiovascular risk factors in non-nephrotic CKD
patients [59, 60].
Nephrotic syndrome patients
So far, the association between the CV risk and
nephrotic syndrome has been investigated only in
small cohorts of patients, generating inconsistent
results [61, 62]. Ordonez et al. [63] have found that
the risk of myocardial infarction and death from
coronary heart disease was, respectively, 5.5 (95 % CI
1.6–18.3) and 2.8 (95 % CI 0.7–11.3) times higher in
patients with nephrotic syndrome (n = 142) than in
the control group (n = 142). Contrary, other authors
failed to confirm the association between the presence
of nephrotic syndrome (steroid-responsive/dependent
nephrotic syndrome during childhood) and an
increased risk of CVD [64].
Dialysis-dependent CKD patients
Hemodialysis patients
The CV mortality in hemodialysis patients is signif-
icantly higher than in the general population [56].
Although a positive association between total serum
cholesterol level and the risk of CVD in the general
population is well documented, studies in dialysis
patients led to conflicting results [60, 65–69]. More-
over, some authors have observed an increased
mortality among patients with lower cholesterol levels
[70, 71]. This phenomenon, referred to as ‘‘reverse
epidemiology’’ or ‘‘reverse causality,’’ may be
explained as a result of confounding by other factors,
specifically protein energy wasting and/or inflamma-
tion. Iseki et al. [68] followed 1,167 hemodialysis
patients for 10 years and found that low cholesterol
concentration was associated with higher mortality as
well as with higher C-reactive protein (CRP) and
lower serum albumin concentrations. However, in a
subgroup of patients with serum albumin values
C4.5 g/dL (n = 128), the adjusted hazard ratio was
1.37 (CI 95 % 1.10–1.69, p = 0.0034), suggesting
that there is a positive relationship between the risk of
death and the level of serum cholesterol in well-
nourished patients. Other authors have supported this
hypothesis, founding that hypercholesterolemia is a
strong risk factor for CV mortality only in the absence
of inflammation (CRP \ 10 mg/L, IL–6 \ 3.09 pg/
mL) or malnutrition (albumin [ 36 g/L) [72].
Kilpatrick et al. [70] followed a cohort of 15,859
maintenance hemodialysis patients for 3 years and
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noted that not only total hypercholesterolemia but also
LDL hypercholesterolemia and hypertriglyceridemia
tend to show a reverse association with survival.
The role of Lp(a), as an independent risk factor for
CV mortality, is well documented [66, 73]. In a study
of 390 patients on HD, the concentration of Lp(a) was
two times higher in dialysis group than in healthy
controls and was significantly associated with CV
mortality [73].
Peritoneal dialysis patients
Peritoneal dialysis patients have a more atherogenic
lipid profile than patients on HD. Therefore, it seems
credible that the CV risk related to dyslipidemia may
be greater in this group of patients. So far, the
association between CVD and dyslipidemia in PD
patients has been investigated in small cohorts, in a
few retrospective studies [74–76]. Nevertheless, some
authors have noted a similar correlation between a low
cholesterol level and malnutrition [77, 78], as well as
the elevated Lp(a) [79] and a higher mortality rate in
this population.
Lipid abnormalities and progression of CKD
In 1982, Moorhead et al. [80] hypothesized that
progression of chronic kidney disease may be medi-
ated by abnormalities in lipid metabolism. It has been
suggested that hyperlipidemia as well as oxidized
Lp(a) and LDL particles may play an important role in
kidney injury [81, 82]. Although the potential mech-
anisms for these abnormalities are not completely
elucidated, it seems credible that circulating LDL, by
binding to the glycosaminoglycans in the glomerular
basement membrane, may lead to an increased
permeability of the membrane. Filtered lipoproteins
may stimulate proliferation of mesangial cells and
contribute to glomerular damage. Even though some
of the filtered lipoproteins are reabsorbed in proximal
tubules, the rest will be altered passing down the
nephron and, if intraluminal pH is close to the
isoelectric point of the apolipoprotein, it will precip-
itate causing tubulointerstitial damage [80, 83].
Attman et al. [84] observed an association between
accumulation of triglyceride-rich apoB-containing
lipoproteins and a more rapid loss of renal function
in a group of patients with non-diabetic kidney
disease. Other authors have noted that oxidized
Lp(a) and LDL particles cause apoptotic cell death
in the vascular wall and in the glomerulus through the
stimulation of the O2 formation [81]. Moreover, it has
been reported that oxidized LDL, but not native LDL,
may induce the loss of nephrin (a principal component
of the slit diaphragm) and apoptosis in human cultured
podocytes, which may lead to proteinuria [82].
Lipid-lowering therapy in pre-dialysis CKD
patients
Cardiovascular outcomes
The evidence that patients at early stages of CKD
benefit from lipid-lowering therapy comes from meta-
analyses and post hoc analyses of large cardiovascular
statin trails in the general population [6–15, 87].
Tonelli et al. [6] analyzed the data from the Pravastatin
Pooling Project (PPP) and showed that moderate
CKD, defined by eGFR of 30–59.9 mL/min/1.73 m2,
was independently associated with increased CV risk.
Pravastatin significantly reduced the incidence of the
primary outcomes (time to myocardial infarction,
coronary death, or coronary revascularization) simi-
larly in the subjects with normal kidney function (HR
0.78, 95 % CI 0.65–0.94) and in the subgroup of 4,491
patients with moderate CKD (HR 0.77, 95 % CI
0.68–0.86). Moreover, in patients with moderate CKD
and high CV risk, pravastatin reduced all-cause
mortality (HR 0.86, 95 % CI 0.74–1.00, p = 0.045).
Therefore, the authors suggested that patients with
impaired kidney function would benefit from statin
therapy more than those with normal renal function
[6]. In another post hoc analysis of data from a
randomized trial of pravastatin 40 mg daily versus
placebo, greater absolute risk reduction in the primary
outcome (time to myocardial infarction, coronary
death, or percutaneous/surgical coronary revasculari-
zation) was observed in patients with CKD (stages 2
and 3) or diabetes (6.4 %) than in individuals without
any of these diseases (3.5 %) [7].
Sever et al. [8] in the Anglo-Scandinavian Cardiac
Outcomes Trial (ASCOT) assessed benefits of statin
therapy in primary prevention of coronary heart
disease in patients with arterial hypertension and
non-fasting total serum cholesterol concentrations
B6.5 mmol/L. In a subgroup analysis of 6,517
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subjects with kidney dysfunction, defined as serum
creatinine concentration 130–200 lmol/L in males
and 110–200 lmol/L in females, atorvastatin (10 mg/
day) reduced the risk of non-fatal myocardial infarc-
tion and cardiovascular death (HR 0.61, 95 % CI
0.44–0.84). In 1,329 patients with impaired renal func-
tion (serum creatinine concentration 130–200 lmol/L
in males and 110–200 lmol/L in females) from the
20,536 adults, who were enrolled into the Heart
Protection Study (HPS), simvastatin use (40 mg/day)
was associated with a significant reduction in major
CV events [9].
Szummer et al. [10] analyzed data from the
nationwide SWEDEHEART registry of over 42,000
patients following myocardial infarction and showed
that statins use was associated with significant reduc-
tion in mortality at 1 year in patients with mild to
severe chronic kidney disease, although the prescrip-
tion of statins at discharge was much less frequent in
patients with severe CKD (29 %) than in those with
normal renal function (81 %).
A post hoc analysis of the Air Force/Texas Coro-
nary Atherosclerosis Prevention Study assessed the
efficiency of lovastatin in the prevention of first major
acute CV event in participants with mild CKD,
defined by eGFR \ 60 mL/min/1.73 m2. A signifi-
cant decrease in CV events such as fatal and non-fatal
coronary events (RR 0.35, 95 % CI 0.13–0.93;
p = 0.03), fatal and non-fatal CV events (RR 0.39,
95 % CI 0.16–0.93; p = 0.03), and coronary revas-
cularization procedures (RR 0.23, 95 % CI 0.07–0.77;
p = 0.01), was found in patients with renal dysfunc-
tion, even after adjustment for potential confounders
[11].
Colhoun et al. [12], reporting data from the
randomized placebo-controlled trial-Collaborative
Atorvastatin Diabetes Study (CARDS), found that
the risk of major CVD events and stroke decreased by
42 and 61 %, respectively, in the subgroup of 970
patients with CKD stage 3 (eGFR 30–60 mL/min/
1.73 m2) treated with atorvastatin.
In a recently performed secondary analysis of the
JUPITER (Justification for the Use of Statins in
Prevention-an Intervention Trial Evaluating Rosu-
vastatin) trial, treatment with rosuvastatin (10 mg
daily) was associated with a 45 % reduction in risk of
myocardial infarction, stroke, or cardiovascular death
(HR 0.55, 95 % CI 0.38–0.82; p = 0.002) and 44 %
reduction in all-cause mortality (HR 0.56, 95 % CI
0.37–0.85; p = 0.005) in participants with moderate
CKD [13].
Holdaas et al. [14] performed a pooled analysis of
30 double-blind, randomized trials to compare the
efficacy of fluvastatin in persons with moderate to
severe CKD (creatinine clearance \ 50 mL/min) and
patients with normal renal function or mild kidney
dysfunction (creatinine clearance C 50 mL/min).
Fluvastatin compared to placebo reduced combined
cardiac death and nonfatal myocardial infarction in
both groups, in patients with moderate to severe renal
insufficiency and in patients with normal renal func-
tion or mild renal insufficiency, by 41 and 30 %,
respectively.
The PREVEND IT (Prevention of Renal and
Vascular End Stage Disease Intervention Trial) is the
only published randomized, double-blind, placebo-
controlled trial performed to asses the role of statins in
patients with microalbuminuria and mild CKD (eGFR
\60 mL/min/1.73 m2). Contrary to previous findings,
subjects treated with pravastatin had no significant risk
reduction in the primary endpoints (cardiovascular
mortality and hospitalization for cardiovascular mor-
bidity) after 4 years (p = 0.64) [85], as well as in
extended 10-year follow-up (p = 0.99) [86].
The Cholesterol Treatment Trialists’ (CTT) Col-
laboration [15] reported a meta-analysis of data from
randomized trials involving at least 1,000 participants
and at least 2-year treatment duration of LDL-
cholesterol-lowering therapy versus control. There
was no evidence for reduction in major CV events
(major coronary events, stroke, or coronary revascu-
larization) in patients with eGFR \30 mL/min/
1.73 m2, although such a reduction was observed in
patients with CKD stages 2 and 3.
A Cochrane Collaboration summarized 26 studies
(25,017 participants) to evaluate the effects of statins
in pre-dialysis CKD. Statins significantly decreased
total and LDL cholesterol, as well as the risk of all-
cause (RR 0.81, 95 % CI 0.74–0.89) and cardiovas-
cular mortality (RR 0.80, 95 % CI 0.70–0.90) in this
group of patients [87].
The Assessment of LEscol in Renal Transplanta-
tion (ALERT) trial [88] compared fluvastatin
(n = 1,050) with placebo (n = 1,052) in patients after
renal transplantation. After a mean follow-up of
5 years, fluvastatin failed to impact the composite
primary endpoint, defined as cardiac death, non-fatal
myocardial infarction, or coronary intervention
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procedure (p = 0.139). However, there was a slight
reduction in cardiac death and non-fatal myocardial
infarction in the group treated with fluvastatin (RR
0.65, 95 % CI 0.48–0.88; p = 0.005). During a 2-year
extension of the ALERT trial, 1,652 renal transplant
recipients who received fluvastatin demonstrated a
lower risk of major cardiac events, cardiac death, or
non-fatal myocardial infarction [16]. Moreover, a post
hoc analysis has suggested a beneficial effect of early
introduction of lipid-lowering therapy in patients after
kidney transplantation: When fluvastatin treatment
was initiated at 0–2 versus [6 years after transplan-
tation, the observed frequency of cardiac death and
non-fatal MI was 3.2 versus 8.2 %, respectively [17].
A possible impact of statins on patient and graft
survival was evaluated among 2,041 first-time renal
allograft recipients also by Wiesbauer et al. [18]. The
authors observed that statin use was associated with
reduced all-cause mortality (adjusted HR 0.64, 95 %
CI 0.48–0.86; p = 0.003) and prolonged patient
survival, while no effect on graft survival was noted.
Only a few lines of evidence suggest a role for other
lipid-lowering agents in the prevention of cardiovas-
cular disease in the CKD population. A post hoc
subgroup analysis of the randomized double-blind,
placebo-controlled Veterans’ Affairs High-Density
Lipoprotein Intervention Trial (VA-HIT) was per-
formed to evaluate the cardiovascular benefits of
gemfibrozil in patients with creatinine clearance
B75 mL/min/1.73 m2 [89]. Treatment with gemfibro-
zil was associated with a lower rate of cumulative
incidence of major cardiovascular events (nonfatal
myocardial infarction, fatal coronary disease, or
stroke) in this subgroup (adjusted HR 0.75, 95 % CI
0.59–0.96). There was, however, higher rate of non-
coronary death and increase in the serum creatinine
concentration in gemfibrozil-treated participants.
Finally, the SHARP (Study of Heart and Renal
Protection) trial [19] was created to assess the bene-
ficial effect of the combination of simvastatin plus
ezetimibe in patients with CKD and no history of
myocardial infarction or coronary revascularization
(Table 1). Of the total 9,270 participants, 6,247 were
not on dialysis at the beginning of the study. They were
initially randomized to receive simvastatin (20 mg)
plus ezetimibe (10 mg), simvastatin (20 mg), or
placebo. There was no difference in the incidence of
adverse events between simvastatin alone and simva-
statin plus ezetimibe group, and after the first year of
observation, patients who initially received simvasta-
tin were re-randomized to simvastatin plus ezetimibe
and placebo groups. The median follow-up was
4.9 years, and the main outcome was the first major
atherosclerotic event, defined as non-fatal myocardial
infarction, coronary death, non-hemorrhagic stroke, or
arterial revascularization procedure (excluded non-
CHD cardiac death and hemorrhagic stroke). On
average, there was a difference in LDL cholesterol of
0.85 mmol/L and a significant 17 % reduction in
major atherosclerotic events (RR 0.83, 95 % CI
0.74–0.94; p = 0.0021) as well as in major vascular
events (RR 0.85, 95 % CI 0.77–0.94; p = 0.0012) in
patients treated with simvastatin plus ezetimibe. The
use of simvastatin plus ezetimibe had no effect on
vascular mortality, but the coronary heart disease was a
cause of death only in 181 patients in this study. During
the follow-up, there was no evidence that this combi-
nation therapy increased the risk of cancer, myopathy,
or hepatitis in CKD patients.
In conclusion, there is evidence suggesting that
patients with CKD stages 2 and 3 may benefit similarly
or even more from statin therapy than those with
normal renal function. Most of this evidence, however,
comes from meta-analyses and post hoc analyses of
trails in the general population and not from prospec-
tive, randomized, controlled study designed specifi-
cally for CKD population. After publication of the
SHARP trial results, the US Food and Drug Admin-
istration (FDA) approved the combination of simva-
statin plus ezetimibe as lipid-lowering treatment
routinely used in kidney disease patients. The K/DOQI
guidelines suggest that patients with pre-dialysis CKD
should be treated according to the NCEP/ATP III
guidelines recommended for the general population
[21].
Renal outcomes
In the last two decades, the nephroprotective effects of
statins have been evaluated in numerous experimental
models as well as in retrospective and prospective
studies (Table 2).
A protective role of rosuvastatin against puromycin
and adriamycin-induced p21-dependent apoptosis in
mouse podocytes has been reported by Cormack-
Aboud et al. [90], suggesting that statins may decrease
proteinuria and delay the progression of CKD. More-
over, statins may exert anti-proteinuric effects through
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the stimulation of Akt activity and inhibition of the
oxLDL-induced apoptosis and loss of nephrin [82].
Fluvastatin significantly decreased urinary albumin
excretion and glomerular sclerosis, as well as
increased nephrin expression in podocytes in a murine
model of HIV-associated nephropathy [91].
In the post hoc analysis of the Greek Atorvastatin
and Coronary Heart Disease Evaluation (GRACE)
study, patients with coronary heart disease and
dyslipidemia treated with atorvastatin (n = 783) had
a 12 % increase in creatinine clearance [92]. This
effect appeared to be dose-related and was more
pronounced among participants with early stages of
CKD. This observation has been confirmed in the
subanalysis of the Treating to New Targets (TNT)
study, in which a significant difference in mean
change from baseline eGFR at the end of the follow-up
was noted between patients with coronary heart
disease treated with atorvastatin in dose 10 mg
(n = 4,829; increase of 3.5 ± 0.14 mL/min/1.73 m2)
and 80 mg daily (n = 4,827; increase of 5.2 ±
0.14 mL/min/1.73 m2) [93]. Tonelli et al. [94] have
reported that compared to placebo, pravastatin
reduced the rate of renal function decline in 1,702
patients with moderate CKD but did not reduce the
risk of a C25 % decline of eGFR. In a subsequent
meta-analysis of 27 randomized, controlled trials,
statin therapy was associated with reduced rate of
decline in eGFR (1.22 mL/min/year slower) com-
pared to placebo [95]. However, this effect was
significant only in the CVD subpopulation but not in
participants with glomerulonephritis, diabetes melli-
tus or hypertension. Navaneethan et al. [87] in a
Cochrane database review did not confirm the bene-
ficial effects of statins on eGFR but found statins
reduced urinary protein excretion in six studies.
Similarly, in two small, prospective, controlled
open-label studies rosuvastatin [96] and atorvastatin
[97] decreased proteinuria in patients with CKD.
Finally, the SHARP trial showed no protection from
reaching ESRD in 6,247 participants not on dialysis at
the beginning of the study [19] (Table 2).
Lipid-lowering therapy in dialysis-dependent CKD
patients
Studies in patients with end-stage renal disease
demonstrated the effectiveness of statins in lowering
LDL cholesterol and similar incidence of adverse
events as in patients without ESRD. The use of statins
had been associated with reduced total and cardiovas-
cular mortality in observational studies. Large ran-
domized controlled trials, however, surprisingly failed
to confirm the benefits in dialyzed patients (Table 1).
Seliger et al. [98] performed a secondary analysis of
the data from the United States Renal Data System
Dialysis Morbidity and Mortality Study Wave 2
(USRDS DMMS-2) finding that treatment with a
statin was associated with lower risk of total (adjusted
RR 0.68, 95 % CI 0.53–0.86; p = 0.002) and cardio-
vascular mortality (adjusted RR 0.63, 95 % CI
0.44–0.91; p = 0.014) both in patients on hemodial-
ysis and peritoneal dialysis. This observation was
confirmed by Mason et al. [99], who analyzed data
from the Dialysis Outcomes and Practice Patterns
Study (DOPPS) and showed a 23 % reduction in the
risk of cardiovascular deaths and a 44 % reduction in
the non-cardiac mortality among HD patients treated
with statins. In a subsequent observational study, the
prescription of statins was associated with a 41 %
lower risk of all-cause mortality in peritoneal dialysis
patients [100].
The 4D Study (Deutsche Diabetes Dialyse Studie)
was a randomized, double-blind, placebo-controlled
study in 1,255 patients with type 2 diabetes mellitus
and dialysis-dependent CKD who were randomized to
receive 20 mg atorvastatin (n = 619) or placebo
(n = 636) (Table 1). A 42 % reduction in the median
LDL cholesterol concentration was observed, to
approximately 70 mg/dL after 4 weeks of lipid-low-
ering therapy. Although the risk of all cardiac events
combined (death from cardiac causes, nonfatal myo-
cardial infarction, coronary artery bypass graft, per-
cutaneous transluminal coronary angioplasty) was
reduced by 18 % in the atorvastatin group (RR 0.82,
95 % CI 0.68–0.99; p = 0.03), the cumulative inci-
dence of the primary endpoint (CV death, nonfatal MI
or stroke) did not differ significantly between atorva-
statin and placebo groups (HR 0.92, 95 % CI
0.77–1.11; p = 0.37). It is of note that coronary heart
disease was a cause of death only in 9 %, while sudden
death, heart failure, and other cardiovascular disease
accounted for 35 % deaths. The incidence of fatal
stroke was unexpectedly higher in the atorvastatin
group compared with placebo (27 vs. 13); however,
the prevalence of combined cerebrovascular events
was similar between both groups [101].
























































































































































































































































































































































































































































































































































































































































































































































































































































































1282 Int Urol Nephrol (2013) 45:1273–1287
123
Similar results were found in the following ran-
domized, double-blind, placebo-controlled study—
AURORA (A Study to Evaluate the Use of Rosuvast-
atin in Subjects on Regular Hemodialysis: An Assess-
ment of Survival and Cardiovascular Events) (Table 1)
[102]. 2,776 patients treated with regular hemodialysis
or hemofiltration for C3 months were randomized to
receive rosuvastatin 10 mg daily (n = 1,391) or
placebo (n = 1,385). The mean follow-up was
3.2 years, and the primary endpoint was defined as
the time to a major cardiovascular event (nonfatal
myocardial infarction, nonfatal stroke, or death from
cardiovascular causes). There was a reduction in the
LDL, total cholesterol, and triglycerides concentra-
tions, by 42.9, 26.6, and 16.2 % respectively, in the
rosuvastatin group. No significant differences in the
primary cardiovascular endpoint were observed
between the rosuvastatin and placebo groups (HR
0.96, 95 % CI 0.84–1.11; p = 0.59). Moreover, there
was no association between the primary endpoint and
the LDL cholesterol level initially and after treatment.
Nevertheless, a post hoc analysis of the diabetic
participants of the AURORA trial have shown that
treatment with rosuvastatin reduced their atheroscle-
rotic coronary events by 32 % (HR 0.68, 95 % CI
0.51–0.90; p = 0.008) [103].
In 9,270 participants of the SHARP trial, 33 %
were dialysis-dependent at randomization (27 % on
hemodialysis and 5 % on peritoneal dialysis)
(Table 1). The reduction in LDL cholesterol level in
dialysis patients (0.6 mmol/L) was smaller compared
to pre-dialysis ones (0.96 mmol/L). Moreover, in this
subgroup, the baseline LDL concentration (2.6 vs.
2.9 mmol/L) and the use of lipid-lowering therapy (54
vs. 65 %) were lower than in non-dialysis-dependent
CKD patients. However, as the authors pointed out,
the SHARP study had no sufficient statistical power to
compare dialysis and pre-dialysis subjects. Given the
overall beneficial effect of simvastatin plus ezetimibe
on the risk of major atherosclerotic events in the
studied population, it may be concluded that these
results are relevant to all patients with CKD [19].
Further studies are needed to investigate the associ-
ation between the use of statins and cardiovascular
mortality in dialysis patients in particular.
One of the possible explanations for the lack of
beneficial cardiovascular effects of statins in dialysis
patients may be a different pathology of arterial wall in
this group. Non-traditional risk factors (uraemia-
specific), such as hyperhomocysteinemia, chronic
fluid volume overload, anemia, increased calcification
and microinflammatory state, might be responsible for
higher incidence of CVD among ESRD subjects [104,
105]. Vascular calcification is found as arterial intima
calcification in atherosclerotic plaques (related to
classical CV risk factors) or arterial media calcifica-
tion (related to calcium/phosphorus disorders and the
duration of HD). It has been documented that this non-
occlusive arterial media calcification is one of the
main, independent predictors of all-cause and CV
mortality in dialysis patients [106]. Moreover, in the
ESRD population, sudden death is more frequent than
atherosclerotic cardiac events and the mechanism of
sudden death is only partially dependent on the
atherosclerotic coronary artery disease. Left ventric-
ular hypertrophy and remodeling comprising fibrosis
and capillary rarefaction, heart failure due to fluid
volume overload, and electrolyte abnormalities caus-
ing arrhythmias may be the main causes of sudden
death in this group of patients [107]. Therefore,
according to Holdaas et al. [103], the selected primary
endpoints in outcome studies should share a common
pathophysiology potentially modifiable by the evalu-
ated treatment.
In summary, having in mind the safety of statins
presented in 4D and AURORA studies and after recent
publication of the data from the SHARP trial, this
lipid-lowering treatment should be administered more
frequently to individuals with CKD stages 1–4, as well
as to those undergoing dialysis. Although atheroscle-
rosis may not be the most frequent cause of death in
patients with impaired kidney function, statins still
reduce the risk of atherosclerotic events in this
population contributing to better survival.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use,
distribution, and reproduction in any medium, provided the
original author(s) and the source are credited.
References
1. Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kid-
ney disease as a risk factor for development of cardio-
vascular disease: a statement from the American Heart
Association Councils on Kidney in Cardiovascular Dis-
ease, High Blood Pressure Research, Clinical Cardiology,
and Epidemiology and Prevention. Circulation 108:2154–
2169
Int Urol Nephrol (2013) 45:1273–1287 1283
123
2. Go AS, Chertow GM, Fan D et al (2004) Chronic kidney
disease and the risks of death, cardiovascular events, and
hospitalization. N Engl J Med 351:1296–1305
3. Shulman NB, Ford CE, Hall WD et al (1989) Prognostic
value of serum creatinine and effect of treatment of
hypertension on renal function: results from the hyper-
tension detection and follow-up program. Hypertension
13:80–93
4. Muntner P, Hamm LL, Kusek JW et al (2004) The prev-
alence of nontraditional risk factors for coronary heart
disease in patients with chronic kidney disease. Ann Intern
Med 140:9–17
5. Baigent C, Keech A, Kearney PM et al (2005) Efficacy and
safety of cholesterol-lowering treatment: prospective
meta-analysis of data from 90,056 participants in 14 ran-
domised trials of statins. Lancet 366:1267–1278
6. Tonelli M, Isles C, Curhan GC et al (2004) Effect of
pravastatin on cardiovascular events in people with
chronic kidney disease. Circulation 110:1557–1563
7. Tonelli M, Keech A, Shepherd J et al (2005) Effect of
pravastatin in people with diabetes and chronic kidney
disease. J Am Soc Nephrol 16:3748–3754
8. Sever PS, Dahlo¨f B, Poulter NR et al (2003) Prevention of
coronary and stroke events with atorvastatin in hyperten-
sive patients who have average or lower-than-average
cholesterol concentrations, in the Anglo-Scandinavian
Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-
LLA): a multicentre randomised controlled trial. Lancet
361:1149–1158
9. Heart Protection Study Collaborative Group (2002) MRC/
BHF Heart Protection Study of cholesterol lowering with
simvastatin in 20,536 high-risk individuals: a randomised
placebo-controlled trial. Lancet 360:7–22
10. Szummer K, Lundman P, Jacobson SH et al (2011)
Association between statin treatment and outcome in
relation to renal function in survivors of myocardial
infarction. Kidney Int 79:997–1004
11. Kendrick J, Shlipak MG, Targher G et al (2010) Effect of
lovastatin on primary prevention of cardiovascular events
in mild CKD and kidney function loss: a post hoc analysis
of the Air Force/Texas Coronary Atherosclerosis Preven-
tion Study. Am J Kidney Dis 55:42–49
12. Colhoun HM, Betteridge DJ, Durrington PN et al (2009)
Effects of atorvastatin on kidney outcomes and cardio-
vascular disease in patients with diabetes: an analysis from
the Collaborative Atorvastatin Diabetes Study (CARDS).
Am J Kidney Dis 54:810–819
13. Ridker PM, MacFadyen J, Cressman M et al (2010) Effi-
cacy of rosuvastatin among men and women with mod-
erate chronic kidney disease and elevated high-sensitivity
C-reactive protein: a secondary analysis from the JUPI-
TER (Justification for the use of statins in prevention-an
intervention trial evaluating rosuvastatin) trial. J Am Coll
Cardiol 55:1266–1273
14. Holdaas H, Wanner C, Abletshauser C et al (2007) The
effect of fluvastatin on cardiac outcomes in patients with
moderate to severe renal insufficiency: a pooled analysis of
double-blind, randomized trials. Int J Cardiol 117:64–74
15. Baigent C, Blackwell L, Emberson J et al (2010) Efficacy
and safety of more intensive lowering of LDL cholesterol:
a meta-analysis of data from 170,000 participants in 26
randomised trials. Lancet 376:1670–1681
16. Holdaas H, Fellstro¨m B, Cole E et al (2005) Long-term
cardiac outcomes in renal transplant recipients receiving
fluvastatin: the ALERT extension study. Am J Transplant
5:2929–2936
17. Holdaas H, Fellstro¨m B, Jardine AG et al (2005) Beneficial
effect of early initiation of lipid-lowering therapy following
renal transplantation. Nephrol Dial Transplant 20:974–980
18. Wiesbauer F, Heinze G, Mitterbauer C et al (2008) Statin
use is associated with prolonged survival of renal trans-
plant recipients. J Am Soc Nephrol 19:2211–2218
19. Baigent C, Landray MJ, Reith C et al (2011) The effects of
lowering LDL cholesterol with simvastatin plus ezetimibe
in patients with chronic kidney disease (Study of Heart and
Renal Protection): a randomised placebo-controlled trial.
Lancet 377:2181–2192
20. EBPG Expert Group on Renal Transplantation (2002)
European best practice guidelines for renal transplantation.
Section IV: long-term management of the transplant
recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia.
Nephrol Dial Transplant 17:26–28
21. Kidney Disease Outcomes Quality Initiative (K/DOQI)
Group (2003) K/DOQI clinical practice guidelines for
management of dyslipidemias in patients with kidney
disease. Am J Kidney Dis 41:1–91
22. Chmielewski M, Carrero JJ, Nordfors L et al (2008) Lipid
disorders in chronic kidney disease: reverse epidemiology
and therapeutic approach. J Nephrol 21:635–644
23. Attman PO, Knight-Gibson C, Tavella M et al (1998) The
compositional abnormalities of lipoproteins in diabetic
renal failure. Nephrol Dial Transplant 13:2833–2841
24. Hirano T, Sakaue T, Misaki A et al (2003) Very low-
density lipoprotein-apoprotein CI is increased in diabetic
nephropathy: comparison with apoprotein CIII. Kidney Int
63:2171–2177
25. Nishizawa Y, Shoji T, Kawagishi T et al (1997) Athero-
sclerosis in uremia: possible roles of hyperparathyroidism
and intermediate density lipoprotein accumulation. Kid-
ney Int Suppl 62:90–92
26. Arnadottir M, Nilsson-Ehle P (1995) Has parathyroid
hormone any influence on lipid metabolism in chronic
renal failure? Nephrol Dial Transplant 10:2381–2382
27. Vaziri ND, Liang K (1997) Down-regulation of VLDL
receptor expression in chronic experimental renal failure.
Kidney Int 51:913–919
28. Kim C, Vaziri ND (2005) Down-regulation of hepatic
LDL receptor-related protein (LRP) in chronic renal fail-
ure. Kidney Int 67:1028–1032
29. Heeringa P, Tervaert JW (2002) Role of oxidized low-
density lipoprotein in renal disease. Curr Opin Nephrol
Hypertens 11:287–293
30. Kasahara J, Kobayashi K, Maeshima Y et al (2004) Clin-
ical significance of serum oxidized low-density lipopro-
tein/beta2-glycoprotein I complexes in patients with
chronic renal diseases. Nephron Clin Pract 98:15–24
31. Deighan CJ, Caslake MJ, McConnell M et al (2000)
Atherogenic lipoprotein phenotype in end-stage renal
failure: origin and extent of small dense low-density
lipoprotein formation. Am J Kidney Dis 35:852–862
1284 Int Urol Nephrol (2013) 45:1273–1287
123
32. O’Neal D, Lee P, Murphy B et al (1996) Low-density
lipoprotein particle size distribution in end-stage renal
disease treated with hemodialysis or peritoneal dialysis.
Am J Kidney Dis 27:84–91
33. Guarnieri GF, Moracchiello M, Campanacci L et al (1978)
Lecithin-cholesterol acyltransferase (LCAT) activity in
chronic uremia. Kidney Int Suppl 8:26–30
34. McLeod R, Reeve CE, Frohlich J (1984) Plasma lipopro-
teins and lecithin:cholesterol acyltransferase distribution
in patients on dialysis. Kidney Int 25:683–688
35. Vaziri ND (2006) Dyslipidemia of chronic renal failure:
the nature, mechanisms, and potential consequences. Am J
Physiol Renal Physiol 290:262–272
36. Vaziri ND, Deng G, Liang K (1999) Hepatic HDL
receptor, SR-B1 and Apo A-I expression in chronic renal
failure. Nephrol Dial Transplantc 14:1462–1466
37. Joven J, Villabona C, Vilella E et al (1990) Abnormalities
of lipoprotein metabolism in patients with the nephrotic
syndrome. N Engl J Med 323:579–584
38. Vaziri ND, Sato T, Liang K (2003) Molecular mechanisms
of altered cholesterol metabolism in rats with spontaneous
focal glomerulosclerosis. Kidney Int 63:1756–1763
39. Vaziri ND (2003) Molecular mechanisms of lipid disor-
ders in nephrotic syndrome. Kidney Int 63:1964–1976
40. Kashyap ML, Srivastava LS, Hynd BA et al (1980) Apo-
lipoprotein CII and lipoprotein lipase in human nephrotic
syndrome. Atherosclerosis 35:29–40
41. Vaziri ND, Kim CH, Phan D et al (2004) Up-regulation of
hepatic Acyl CoA: diacylglycerol acyltransferase-1
(DGAT-1) expression in nephrotic syndrome. Kidney Int
66:262–267
42. Ohta T, Matsuda I (1981) Lipid and apolipoprotein levels
in patients with nephrotic syndrome. Clin Chim Acta
117:133–143
43. Alexander JH, Schapel GJ, Edwards KD (1974) Increased
incidence of coronary heart disease associated with com-
bined elevation of serum triglyceride and cholesterol
concentrations in the nephrotic syndrome in man. Med J
Aust 2:119–122
44. Joven J, Rubie´s-Prat J, Espinel E et al (1987) High-density
lipoproteins in untreated idiopathic nephrotic syndrome
without renal failure. Nephrol Dial Transplant 2:149–153
45. Cheung AK, Wu LL, Kablitz C et al (1993) Atherogenic
lipids and lipoproteins in hemodialysis patients. Am J
Kidney Dis 22:271–276
46. Rapoport J, Aviram M, Chaimovitz C et al (1978)
Defective high-density lipoprotein composition in patients
on chronic hemodialysis. A possible mechanism for
accelerated atherosclerosis. N Engl J Med 299:1326–1329
47. Attman PO, Alaupovic P (1991) Lipid and apolipoprotein
profiles of uremic dyslipoproteinemia-relation to renal
function and dialysis. Nephron 57:401–410
48. Na¨sstro¨m B, Stegmayr B, Olivecrona G et al (2004)
Lipoprotein lipase in hemodialysis patients: indications
that low molecular weight heparin depletes functional
stores, despite low plasma levels of the enzyme. BMC
Nephrol 5:17
49. Blankestijn PJ, Vos PF, Rabelink TJ et al (1995) High-flux
dialysis membranes improve lipid profile in chronic he-
modialysis patients. J Am Soc Nephrol 5:1703–1708
50. Attman PO, Samuelsson OG, Moberly J et al (1999)
Apolipoprotein B-containing lipoproteins in renal failure:
the relation to mode of dialysis. Kidney Int 55:1536–1542
51. Kronenberg F, Lingenhel A, Neyer U et al (2003) Preva-
lence of dyslipidemic risk factors in hemodialysis and
CAPD patients. Kidney Int Suppl 84:113–116
52. Kronenberg F, Ko¨nig P, Neyer U et al (1995) Multicenter
study of lipoprotein(a) and apolipoprotein(a) phenotypes
in patients with end-stage renal disease treated by he-
modialysis or continuous ambulatory peritoneal dialysis.
J Am Soc Nephrol 6:110–120
53. Johansson AC, Samuelsson O, Attman PO et al (2000)
Dyslipidemia in peritoneal dialysis–relation to dialytic
variables. Perit Dial Int 20:306–314
54. Prinsen BH, Rabelink TJ, Romijn JA et al (2004) A broad-
based metabolic approach to study VLDL apoB100
metabolism in patients with ESRD and patients treated
with peritoneal dialysis. Kidney Int 65:1064–1075
55. Steele J, Billington T, Janus E et al (1989) Lipids, lipo-
proteins and apolipoproteins A-I and B and apolipoprotein
losses in continuous ambulatory peritoneal dialysis. Ath-
erosclerosis 79:47–50
56. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epide-
miology of cardiovascular disease in chronic renal disease.
Am J Kidney Dis 32:112–119
57. Sarnak MJ, Coronado BE, Greene T et al (2002) Cardio-
vascular disease risk factors in chronic renal insufficiency.
Clin Nephrol 5:327–335
58. Coresh J, Longenecker JC, Miller ER III et al (1998)
Epidemiology of cardiovascular risk factors in chronic
renal disease. J Am Soc Nephrol 9:24–30
59. Kronenberg F, Kuen E, Ritz E et al (2000) Lipopro-
tein(a) serum concentrations and apolipoprotein(a) pheno-
types in mild and moderate renal failure. J Am Soc
Nephrol 11:105–115
60. Kronenberg F, Neyer U, Lhotta K et al (1999) The low
molecular weight apo(a) phenotype is an independent
predictor for coronary artery disease in hemodialysis
patients: a prospective follow-up. J Am Soc Nephrol
10:1027–1036
61. Berlyne GM, Mallick NP (1969) Ischaemic heart-
disease as a complication of nephrotic syndrome. Lancet
2:399–400
62. Wass V, Cameron JS (1981) Cardiovascular disease and
the nephrotic syndrome: the other side of the coin. Neph-
ron 27:58–61
63. Ordon˜ez JD, Hiatt RA, Killebrew EJ et al (1993) The
increased risk of coronary heart disease associated with
nephrotic syndrome. Kidney Int 44:638–642
64. Lechner BL, Bockenhauer D, Iragorri S et al (2004) The
risk of cardiovascular disease in adults who have had
childhood nephrotic syndrome. Pediatr Nephrol
19:744–748
65. Cheung AK, Sarnak MJ, Yan G et al (2000) Atheroscle-
rotic cardiovascular disease risks in chronic hemodialysis
patients. Kidney Int 58:353–362
66. Cressman MD, Heyka RJ, Paganini EP et al (1992)
Lipoprotein(a) is an independent risk factor for cardio-
vascular disease in hemodialysis patients. Circulation
86:475–482
Int Urol Nephrol (2013) 45:1273–1287 1285
123
67. Hahn R, Oette K, Mondorf H et al (1983) Analysis of
cardiovascular risk factors in chronic hemodialysis
patients with special attention to the hyperlipoproteine-
mias. Atherosclerosis 48:279–288
68. Iseki K, Yamazato M, Tozawa M et al (2002) Hypocho-
lesterolemia is a significant predictor of death in a cohort of
chronic hemodialysis patients. Kidney Int 61:1887–1893
69. Kalantar-Zadeh K, Kopple JD, Block G et al (2001) A
malnutrition-inflammation score is correlated with mor-
bidity and mortality in maintenance hemodialysis patients.
Am J Kidney Dis 38:1251–1263
70. Kilpatrick RD, McAllister CJ, Kovesdy CP et al (2007)
Association between serum lipids and survival in hemod-
ialysis patients and impact of race. J Am Soc Nephrol
18:293–303
71. Lowrie EG, Lew NL (1990) Death risk in hemodialysis
patients: the predictive value of commonly measured
variables and an evaluation of death rate differences
between facilities. Am J Kidney Dis 15:458–482
72. Liu Y, Coresh J, Eustace JA et al (2004) Association
between cholesterol level and mortality in dialysis
patients: role of inflammation and malnutrition. JAMA
291:451–459
73. Koda Y, Nishi S, Suzuki M et al (1999) Lipoprotein(a) is a
predictor for cardiovascular mortality of hemodialysis
patients. Kidney Int Suppl 71:251–253
74. Webb AT, Brown EA (1993) Prevalence of symptomatic
arterial disease and risk factors for its development in
patients on continuous ambulatory peritoneal dialysis.
Perit Dial Int 13:406–408
75. Olivares J, Cruz C, Gas JM et al (1992) Evolution of lipid
profiles in long-term peritoneal dialysis. Adv Perit Dial
8:373–375
76. Gault MH, Longerich L, Prabhakaran V et al (1991)
Ischemic heart disease, serum cholesterol, and apolipo-
proteins in CAPD. ASAIO Trans 37:513–514
77. Piccoli GB, Quarello F, Salomone M et al (1995) Are
serum albumin and cholesterol reliable outcome markers
in elderly dialysis patients? Nephrol Dial Transplant
10:72–77
78. Sreedhara R, Avram MM, Blanco M et al (1996) Preal-
bumin is the best nutritional predictor of survival in he-
modialysis and peritoneal dialysis. Am J Kidney Dis
28:937–942
79. Iliescu EA, Marcovina SM, Morton AR et al (2002)
Apolipoprotein(a) phenotype and lipoprotein(a) level
predict peritoneal dialysis patient mortality. Perit Dial Int
22:492–499
80. Moorhead JF, Chan MK, El-Nahas M et al (1982) Lipid
nephrotoxicity in chronic progressive glomerular and
tubulo-interstitial disease. Lancet 2:1309–1311
81. Galle J, Heermeier K, Wanner C (1999) Atherogenic
lipoproteins, oxidative stress, and cell death. Kidney Int
Suppl 71:62–65
82. Bussolati B, Deregibus MC, Fonsato V et al (2005) Statins
prevent oxidized LDL-induced injury of glomerular
podocytes by activating the phosphatidylinositol 3-kinase/
AKT-signaling pathway. J Am Soc Nephrol 16:1936–1947
83. Gyebi L, Soltani Z, Reisin E (2012) Lipid Nephrotoxicity:
new concept for an old disease. Curr Hypertens Rep
14:177–181
84. Attman PO, Alaupovic P, Samuelsson O (1999) Lipopro-
tein abnormalities as a risk factor for progressive nondia-
betic renal disease. Kidney Int Suppl 71:14–17
85. Asselbergs FW, Diercks GF, Hillege HL et al (2004)
Effects of fosinopril and pravastatin on cardiovascular
events in subjects with microalbuminuria. Circulation
110:2809–2816
86. Brouwers FP, Asselbergs FW, Hillege HL et al (2011)
Long-term effects of fosinopril and pravastatin on car-
diovascular events in subjects with microalbuminuria: ten
years of follow-up of Prevention of Renal and Vascular
End-stage Disease Intervention Trial (PREVEND IT). Am
Heart J 161:1171–1178
87. Navaneethan SD, Pansini F, Perkovic V et al (2009) HMG
CoA reductase inhibitors (statins) for people with chronic
kidney disease not requiring dialysis. Cochrane Database
Syst Rev 2:7784
88. Holdaas H, Fellstro¨m B, Jardine AG et al (2003) Effect of
fluvastatin on cardiac outcomes in renal transplant recip-
ients: a multicentre, randomised, placebo-controlled trial.
Lancet 361:2024–2031
89. Tonelli M, Collins D, Robins S et al (2004) Gemfibrozil for
secondary prevention of cardiovascular events in mild to
moderate chronic renal insufficiency. Kidney Int
66:1123–1130
90. Cormack-Aboud FC, Brinkkoetter PT, Pippin JW et al
(2009) Rosuvastatin protects against podocyte apoptosis in
vitro. Nephrol Dial Transplant 24:404–412
91. Sakurai N, Kuroiwa T, Ikeuchi H et al (2009) Fluvastatin
prevents podocyte injury in a murine model of HIV-
associated nephropathy. Nephrol Dial Transplant
24:2378–2383
92. Athyros VG, Mikhailidis DP, Papageorgiou AA et al
(2004) The effect of statins versus untreated dyslipidaemia
on renal function in patients with coronary heart disease. A
subgroup analysis of the Greek atorvastatin and coronary
heart disease evaluation (GREACE) study. J Clin Pathol
57:728–734
93. Shepherd J, Kastelein JJ, Bittner V et al (2007) Effect of
intensive lipid lowering with atorvastatin on renal function
in patients with coronary heart disease: the Treating to New
Targets (TNT) study. Clin J Am Soc Nephrol 2:1131–1139
94. Tonelli M, Isles C, Craven T et al (2005) Effect of prav-
astatin on rate of kidney function loss in people with or at
risk for coronary disease. Circulation 112:171–178
95. Sandhu S, Wiebe N, Fried LF et al (2006) Statins for
improving renal outcomes: a meta-analysis. J Am Soc
Nephrol 17:2006–2016
96. Abe M, Maruyama N, Yoshida Y et al (2011) Efficacy
analysis of the lipid-lowering and renoprotective effects of
rosuvastatin in patients with chronic kidney disease.
Endocr J 58:663–674
97. Bianchi S, Bigazzi R, Caiazza A et al (2003) A controlled,
prospective study of the effects of atorvastatin on pro-
teinuria and progression of kidney disease. Am J Kidney
Dis 41:565–570
98. Seliger SL, Weiss NS, Gillen DL et al (2002) HMG-CoA
reductase inhibitors are associated with reduced mortality
in ESRD patients. Kidney Int 61:297–304
99. Mason NA, Bailie GR, Satayathum S et al (2005) HMG-
coenzyme a reductase inhibitor use is associated with
1286 Int Urol Nephrol (2013) 45:1273–1287
123
mortality reduction in hemodialysis patients. Am J Kidney
Dis 45:119–126
100. Lee JE, Oh KH, Choi KH et al (2011) Statin therapy is
associated with improved survival in incident peritoneal
dialysis patients: propensity-matched comparison. Neph-
rol Dial Transplant 26:4090–4094
101. Wanner C, Krane V, Ma¨rz W et al (2005) Atorvastatin in
patients with type 2 diabetes mellitus undergoing hemod-
ialysis. N Engl J Med 353:238–248
102. Fellstro¨m BC, Jardine AG, Schmieder RE et al (2009)
Rosuvastatin and cardiovascular events in patients under-
going hemodialysis. N Engl J Med 360:1395–1407
103. Holdaas H, Holme I, Schmieder RE et al (2011) Rosu-
vastatin in diabetic hemodialysis patients. J Am Soc
Nephrol 22:1335–1341
104. Zoccali C (2000) Cardiovascular risk in uraemic
patients—is it fully explained by classical risk factors?
Nephrol Dial Transplant 15:454–457
105. Amann K, Tyralla K, Gross ML et al (2003) Special
characteristics of atherosclerosis in chronic renal failure.
Clin Nephrol 60:13–21
106. London GM, Gue´rin AP, Marchais SJ et al (2003) Arterial
media calcification in end-stage renal disease: impact on
all-cause and cardiovascular mortality. Nephrol Dial
Transplant 18:1731–1740
107. Kanbay M, Afsar B, Goldsmith D et al (2010) Sudden
death in hemodialysis: an update. Blood Purif 30:135–145
Int Urol Nephrol (2013) 45:1273–1287 1287
123
